| Date | Title | Description |
| 17.02.2021 | The Government Can — And Should — Send High-Quality Masks To Every American | Link to full article from The Washington Post
As more-contagious variants of the coronavirus spread, the Centers for Disease Control and Prevention is urging people to wear better masks, or to double up on the ones they have. The Biden adm... |
| 08.11.2020 | A National COVID-19 Confidence Project: Job No. 1 For President Elect Biden | Full article from STAT News
President-elect Joe Biden faces many grave challenges. The one we believe to be paramount is that the lack of coherent, national leadership to date in the face of the Covid-19 pandemic has left Americans to resp... |
| 22.10.2020 | Protecting Biomedical Innovation as A National Security Asset | Full article from BioCentury
In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest of the wo... |
| 20.10.2020 | Essential Workers Need Better Masks | Link to full article from HBR
With a vaccine still months away for most people in the United States and years away in many other countries, a specific kind of mask is the most effective way to immediately protect essential workers in a wid... |
| 16.09.2020 | David Beier Op-Ed: Vaccine Hesitancy: Why American Values Matter | Link to full article from BioCentury
More than a third of Americans tell polls they would not take a vaccine to prevent COVID-19, the most devastating disease in 100 years. Vaccine hesitancy is even higher among Black people — hard-hit in ... |
| 21.07.2020 | David Beier Op-Ed: The Time Has Come for a Major National Effort on Mask Innovation | Full article from Medium
We the undersigned, scientists and public health advocates, urge public officials and leaders in communities and the private sector — corporate and nonprofit — to step up our efforts to stop the spread of the COVID... |
| 18.06.2020 | David Beier Op-Ed: We Need Better Masks | Link to full in article from HBR
With 21 U.S. states experiencing a rise in Covid-19 cases just weeks after reopening, it’s clear that maintaining control of the pandemic without lockdowns is proving to be a challenge. To not only stay ope... |
| 01.05.2020 | David Beier Op-Ed: A Plan to Safely Reopen the U.S. Despite Inadequate Testing | Link to full article from HBR
For regions shut down due to Covid-19 to safely begin to reopen, we need ways to keep R — the average number of additional people infected by each infected person — under one, the threshold below which epidemi... |
| 26.02.2020 | David Beier Op-Ed: We Need a Cheap Way to Diagnose Coronavirus | Link to full article from HBR
Covid-19, the new coronavirus, is on the verge of spreading across the world. Large clusters of cases are emerging outside China in South Korea, Italy, and Iran, and the Centers for Disease Control and Prevent... |
| 19.02.2020 | David Beier Op-Ed: A New Drug Pricing Social Contract: The Great American Drug Deal | Article from Medium
In The Great American Drug Deal, biotech investor Peter Kolchinsky outlines a vision for the future of the pharmaceutical industry. It’s a future in which the interests of society align both with the firms developing ne... |
| 23.01.2020 | Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma | Link to full release from Epizyme
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has grant... |
| 14.01.2020 | Innovation in biotech R&D: New resources offer new hope | Link to full Op Ed on STAT NEWS
Public optimism about American health care seems in short supply if you read the news, which is dominated by coverage of partisan fights over the Affordable Care Act and the continuing crisis of opioid addic... |
| 10.01.2020 | Lilly Announces Agreement to Acquire Dermira | Link to full article from Dermira |
| 07.01.2020 | Galecto and PharmAkea Merge to Create Strong Clinical-Stage Company Developing -in-Class Therapeutics in Fibrosis and Cancer | Link to full release from GlobeNewswire
Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately held San Diego-... |
| 07.01.2020 | Galecto and PharmaKea merge to create strong clinical-stage company | Link to full press release from Galecto
San Diego, CA/Copenhagen, Denmark, January 7, 2020 – Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and can... |
| 07.01.2020 | Galecto to merge with onetime Celgene partner PharmAkea | https://www.fiercebiotech.com/biotech/galecto-to-merge-one-time-celgene-partner-pharmakea
Galecto is set to merge with PharmAkea. The deal will see Denmark’s Galecto incorporate in the U.S. and add a clinical-phase treatment for idiopathic... |
| 10.12.2019 | Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis | Full article from Dermira
MENLO PARK, Calif.–(BUSINESS WIRE)– Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the milli... |
| 26.09.2019 | David Beier Op-Ed: A Plan to Address California’s Quiet Crisis: Children’s Mental Health | Link to full article in Medium
California’s kids are in crisis, and the issue isn’t getting the attention it deserves. It’s a crisis of too many and too few: too many kids with mental health problems, and too few resources to address them.... |
| 25.09.2019 | Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409) | Link to full release from Blade
Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready autotaxin inhibitor... |
| 27.08.2019 | Synchronicity Pharma Highlights New Research Demonstrating Beneficial Effects of Modulating Core Clock Proteins in Glioblastoma Stem Cells | Read full article from Synchronicity Pharma
San Francisco August 27, 2019 – Synchronicity Pharma (“Synchronicity”), a clinical-stage company focused on therapeutic translation of circadian clock biology, today announced the publication of ... |
| 27.06.2019 | Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis | Read full release on Dermira’s website
BARCELONA, Spain & MENLO PARK, Calif.–(BUSINESS WIRE)–Jun. 25, 2019– Almirall, S.A. (BME: ALM) and Dermira, Inc. (NASDAQ: DERM) announced today that Almirall has exercised its option to license ri... |
| 07.05.2019 | David Beier Op-Ed: Time for Action on America’s Sleep Crisis | Link to full article on Medium.com
Sleep deprivation is killing us.
More than one third of American adults report they get fewer than the 7 hours of sleep the Centers for Disease Control calls for. This qualifies sleep deprivation as a pu... |
| 19.03.2019 | David Beier Op-Ed: FDA Reform: It’s Time To Act, But Not As An Independent Agency | Link to full article on Health Affairs
In a rare exercise in bipartisan leadership, former Food and Drug Administration (FDA) commissioners of both political parties called, in the January 2019 issue of Health Affairs, for the FDA to bec... |
| 25.01.2019 | David Beier Op-Ed: The Midterm’s Biggest Winners: Medicaid And Rural America | Link to full article
Voters in the 2018 midterm, especially in rural America, offered a ringing endorsement of Medicaid and a desire to protect, preserve, and improve the ACA. In December a Texas judge struck down the entirety of the Affor... |
| 04.01.2019 | Artificial Intelligence keeps Gov.-elect Newsom up at night. Here’s what he can do about it | Article from The Sacramento Bee
An out of control trolley rushes toward five people tied to the tracks. Your hand is on the switch that can redirect the trolley to a side track. But the side track has one person similarly incapacitated. Do... |
| 20.12.2018 | David Beier Op-Ed: The right way to address prescription drug costs | Link to article at Stat News
With a new Democratic majority in the House pledging to address the rising cost of health care — including prescription drugs — a fundamental question arises: Will lawmakers focus on the real issues that can dr... |
| 26.11.2018 | David Beier Op-Ed: How business leaders of the world can unite to end the trade war if the US and China are not up to the task | Full article at South China Morning Post
The ongoing US-China trade war bodes poorly for global economic growth. There are steps we can take to prevent the current tit-for-tat escalation from becoming a full-blown cancer that sickens the g... |
| 24.10.2018 | David Beier Appointed to NAM Action Collaborative | David Beier is pleased to be appointed to join public health colleagues in an Action Collaborative established by the National Academy of Medicine to address the challenges of the Opioid crisis. This impressive set of experts come from mult... |
| 12.10.2018 | Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis | Full article from Dermira
MENLO PARK, Calif., Sept. 5, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the milli... |
| 14.09.2018 | David Beier Op-Ed: Advancing Health in California | Full article in Medium
“One of the biggest problems in healthcare,” says Diana Dooley, chief of staff to California Governor Jerry Brown and the state’s longtime secretary of health and human services, “is that we pay for the treatment of ... |
| 14.09.2018 | David Beier and Andrew Sullivan Op-Ed: Russian bots are taking aim at U.S. public health | Full article in STAT News
It almost makes sense, in a most devious way, that the Russian government used a disinformation campaign to try to sway the 2016 elections. That campaign has been front and center in many news cycles. But a disinf... |
| 29.06.2018 | Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis | Link to full article from Dermira
MENLO PARK, Calif., June 29, 2018 (GLOBE NEWSWIRE) — Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, ne... |
| 22.06.2018 | David Beier Op Ed: America’s human infrastructure is the keystone challenge of our time | Full article in The Hill
When the Soviet Union’s Sputnik satellite entered the earth’s orbit in 1957, a race of historic urgency began. Would America lose the space race to its archrival? Our national response was decisive and strategic. I... |
| 15.06.2018 | David Beier Op-Ed: America’s human infrastructure is the keystone challenge of our time | Link to full article in The Hill
When the Soviet Union’s Sputnik satellite entered the earth’s orbit in 1957, a race of historic urgency began. Would America lose the space race to its archrival? Our national response was decisive and stra... |
| 31.05.2018 | Madrigal Achieves Liver Biopsy Endpoints in Patients with NASH | Full article from Madrigal Pharmaceuticals
CONSHOHOCKEN, Pa., May 31, 2018 — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced positive top-line, 36-week results from a Phase 2 clinical trial in patients with biopsy-proven non-... |
| 23.05.2018 | David Beier Op Ed: Trump’s Drug Pricing Plan: A Web of Contradictions or the Beginnings of a Deal? | Full article in Morning Consult
President Donald Trump has offered a comprehensive set of policies to address drug pricing. The critique that his plan is pro-pharmaceutical industry is wrong.
In this piece, I offer praise and skeptical co... |
| 20.04.2018 | Incentives in Drug Development: Orphan Drugs & Antibiotics | David Beier & Dayton Misfeldt
April 23, 2018
University of California Berkeley |
| 20.04.2018 | David Beier Op-Ed: On drug pricing, Trump could rely on bluster and bad ideas. But there’s a better alternative | Full article in Stat News
As President Trump prepares to give a speech next week to address the issue of prescription drug prices, we wonder if we will witness the Trump of the presidential campaign, who slams the pharmaceutical industry f... |
| 06.04.2018 | Biosimilar Drugs: Panacea for Health Care Costs? Not Exactly | This article is an edited version of a longer piece on biosimilars. For those interested in more details here is a link to the longer version along with the footnotes or endnotes that provide references.
Biosimilars are important to the ... |
| 08.03.2018 | Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board | CAMBRIDGE, Mass., March 8, 2018 /PRNewswire/ — Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that it has added to its Board of Directors, expanded its clinical leadership team, and established a Scientific Advisory Board.
“... |
| 14.02.2018 | Twist Bioscience Launches Exome and Custom Target Enrichment Solutions for Genomics and Clinical Researchers Conducting Next-Generation Sequencing | - |
| 25.01.2018 | Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock | - |
| 10.01.2018 | Governor Brown Announces: David Beier Appointment to the Little Hoover Commission | Announcement at CA.Gov
David Beier, 69, of San Francisco, has been reappointed to the Milton Marks “Little Hoover” Commission on California State Government Organization and Economy, where he has served since 2014. Beier has been managing ... |
| 07.01.2018 | WuXi Global Forum 2018 – A Celebration of Global Partnerships | David Beier
January 9, 2018
San Francisco, CA
Event link |
| 06.01.2018 | Sachs Neuroscience Innovation Forum | Investor Roundtable
Manuel Lopez
January 7, 2018
San Francisco, CA |
| 04.01.2018 | Madrigal: This Year’s Best Midcap Stock Was Virtually Unknown 6 Months Ago | Article in Bloomberg
Madrigal Pharmaceuticals Inc. — a player in the blockbuster contest to develop treatments for the liver disease known as NASH — surged more than 500 percent this year, poised to finish 2017 as the best performing stock... |
| 04.01.2018 | David Beier Op-Ed: The NIH is in danger of losing its edge in creating biomedical innovations | Article in Stat News
In Ernest Hemingway’s “The Snows of Kilimanjaro,” the protagonist dies from an infection after scratching his leg on a thorn. That was in 1936, before the introduction of penicillin. It’s hard to imagine a world in whi... |
| 19.12.2017 | Madrigal Pharmaceuticals Prices Public Offering of Common Stock | Release at Yahoo Finance
CONSHOHOCKEN, Pa., Dec. 18, 2017 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for car... |
| 18.12.2017 | Arcus Biosciences Appoints David Beier to Board of Directors | Article at CNBC
HAYWARD, Calif.–(BUSINESS WIRE)– Arcus Biosciences, a clinical stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of David Beier, J.D. to its Board of Dire... |
| 06.12.2017 | Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial | Full Press Release from Madrigal
— Statistically significant improvement in the relative decrease in liver fat in patients treated with MGL-3196 compared with placebo, determined by magnetic resonance imaging-estimated proton density fat f... |
| 30.11.2017 | David Beier Op-Ed: What Trump’s Health Secretary Needs to Answer | Article in Morning Consult
Ten months ago, we wrote about Health and Human Services nominee Tom Price and suggested topics for the Senate to explore in his confirmation hearings. No one guessed that after being confirmed he would fall from... |
| 30.11.2017 | David Beier Op-Ed: Drug price reforms that limit incentives for biomedical innovation are shortsighted | Article in Stat News
The ongoing furor over the price of prescription pharmaceuticals has become so intense that even an august, establishment group like the National Academy of Sciences, Engineering, and Medicine (NAS) cannot help but wei... |
| 14.11.2017 | PLENARY: A New Generation of Philanthropy Joins the Battle Against Disease | David Beier
November 14, 2017
San Francisco, CA
Event link |
| 09.11.2017 | David Beier Op-Ed: A Tax on Robots Is a Tax on Jobs | Article from Inside Sources
Legendary baseball player and fractured linguist Yogi Berra is claimed to have said, “It’s deja vu all over again.” Well, when we look for the descendants of British Luddites – the early 19th century protestors ... |
| 06.11.2017 | David Beier Quoted in STAT Article: They had power and status on the East Coast. So why did these health care gurus decamp for California? To change the world | Link to STAT post
PALO ALTO, Calif. — It’s easy to think, from the headlines, that the future of health care is being forged on Capitol Hill. But the traditional centers of power and influence are losing ground — and talent — to the fertil... |
| 01.11.2017 | A State of Emergency: Integrative Approaches to Addiction and the Opioid Epidemic | - |
| 10.10.2017 | WSGR: Healthcare Innovations Venture Investment Forum | Carl Goldfischer, Matt Kronmiller
December 6 - 8, 2017
Austin, Texas |
| 28.09.2017 | Immunogenomics 2017 | Shaping The Future of Human Health
Fred Craves, Manuel Lopez, and Minqi Li
October 2 - 4, 2017
Huntsville, AL
Event link |
| 14.09.2017 | New CIMZIA® Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress | - |
| 13.09.2017 | Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients | MENLO PARK, Calif., Sept. 13, 2017 — Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living wit... |
| 28.08.2017 | CLSA Expands Board Of Directors With Industry And Academic Leaders From Across The Golden State |
SAN FRANCISCO and SAN DIEGO – California Life Sciences Association (CLSA), the statewide public policy and business leadership trade association representing California’s innovative life sciences industry, has added to the diverse backgro... |
| 01.08.2017 | David Beier Op-Ed: Pharma and the Opioid Crisis: In Search of Solutions | Article in Morning Consult
|
| 21.07.2017 | Dayton Misfeldt Op-Ed: Orphan Diseases Or Population Health? Policy Choices Drive Venture Capital Investments | Article in Health Affairs
The US exhibits a remarkable pipeline of biopharmaceutical innovation, with 170 new drugs and biologics launched into the market between 2011 and 2015 and another 22 drugs approved in 2016. A striking feature of t... |
| 09.07.2017 | 10th China Biotechnology Industry Conference – the Biomedical and Health Industry Investment and Financing Summit Forum | GF Securities, GF Xinde Investment Management Co., Ltd. (“GF Xinde”) and Bay City Capital, LLC (“Bay City Capital”), in collaboration with the China Society of Biotechnology and the China Pharmaceutical Enterprises Development Promote Assoc... |
| 09.07.2017 | Bay City Capital and GF Xinde Announce Collaboration on Unique Fund | GF Securities, GF Xinde Investment Management Co., Ltd. (“GF Xinde”) and Bay City Capital, LLC (“Bay City Capital”).
Bay City Capital and GF Xinde announced a new life sciences fund — Bay City Capital GF Xinde International Life Sciences U... |
| 06.07.2017 | David Beier Op-Ed: China Set To Accelerate Life Science Innovation | Article in Forbes
|
| 16.06.2017 | David Beier Op-Ed: Reform Prescription Drug Labeling to Benefit Patients and Their Doctors | https://morningconsult.com/opinions/reform-prescription-drug-labeling-benefit-patients-doctors/ |
| 24.05.2017 | David Beier Op-Ed: What President Trump can learn from Gov. Brown | Article in The Sacramento Bee
|
| 18.05.2017 | David Beier Op-Ed: Human Genome Editing: Who Gets to Decide? | Article in Scientific American
|
| 16.05.2017 | David Beier Op-Ed: Why Are The Children Crying? | Article in Morning Consult
|
| 01.05.2017 | David Beier Op-Ed: Understanding Of Cell Biology By Creating A Cell Atlas Requires Collaboration | Article in Medium
|
| 03.04.2017 | Cydan Development Announces the Acquisition of Its First Rare Disease Spin-out, Vtesse, Inc. by Sucampo Pharmaceuticals, Inc. | Link to Release
Cambridge, Mass., April 3, 2017 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, today announces that Vtesse, Inc., ... |
| 27.03.2017 | Bridge Medicines Appoints William J. Polvino, M.D., As Chief Executive Officer | New York, NY — Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the appointment of William J. Polvino, M.D., as Chief Executive Officer (CEO). In... |
| 21.03.2017 | Omicia Rebrands as Fabric Genomics | Oakland, CA and Phoenix, AZ — Omicia today announced that it has rebranded and renamed the organization to better reflect the company’s ability to uniquely deliver clinical quality genomic data insights. Now known as Fabric Genomics TM, the... |
| 16.03.2017 | Merus Named BioCapital Europe 2017 Company of the Year | Utrecht, The Netherlands — Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has been named BioCapital Europe’s Company of the Year for 2017. I... |
| 15.03.2017 | David Beier Op-Ed: The World Is Completely Unprepared for a Global Pandemic | Article in Harvard Business Review
In 2003 a doctor with SARS unknowingly infected several guests while staying at a Hong Kong hotel, and overnight the virus reached across the globe. China is currently battling a bird flu that kills nearl... |
| 03.03.2017 | David Beier Op-Ed: Drug Price Transparency Bill Will Not Lower Rx Costs | Article in SF Chronicle |
| 08.02.2017 | 10th European Life Science CEO Forum | Private Equity and VC Panel
Lionel Carnot
March 6-7, 2017
Zurich, Switzerland
Event link |
| 07.02.2017 | Epizyme Elects Kevin Conroy to its Board of Directors | Cambridge, MA — Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has elected industry veteran Kevin Conroy, chairman and chief executive officer of... |
| 20.01.2017 | Accriva Diagnostics Acquired by Werfen and Instrumentation Laboratory | http://www.accriva.com/uploads/assets/Press-Release-Issued-by-Accriva-January-20-2017-FINAL.pdf
Accriva Diagnostics, a Warburg Pincus portfolio company, announced today the definitive agreement with Werfen, a privately held medical diagnos... |
| 20.01.2017 | Accriva Diagnostics Acquired by Werfen and Instrumentation Laboratory | San Diego, CA — Accriva Diagnostics, a Warburg Pincus portfolio company, announced today the definitive agreement with Werfen, a privately held medical diagnostics firm headquartered in Barcelona, Spain, and its subsidiary Instrumentation L... |
| 21.12.2016 | Incyte and Merus Announce Global Strategic Research Collaboration | Wilmington, DE and Utrecht, The Netherlands – Incyte Corporation (NASDAQ:INCY) and Merus N.V. (NASDAQ:MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, discovery and devel... |
| 29.11.2016 | Vtesse Receives Rare Pediatric Disease Designation for VTS-270 for the Treatment of Niemann-Pick Type C1 Disease | Gaithersburg, MD — Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease des... |
| 18.11.2016 | PharmAkea Extends Collaboration with Celgene Corporation | San Diego, CA — PharmAkea Inc. announced the extension of their strategic collaboration with Celgene Corporation which was established to leverage PharmAkea’s proprietary drug discovery platform and novel small-molecule therapies targeting ... |
| 15.11.2016 | Merus Announces Favorable Decisions in Europe and Japan for Patent Covering Genetically-Modified Mice | Utrecht, The Netherlands — Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it received two favorable rulings for its European patent EP 2147594 ... |
| 03.11.2016 | Interleukin Genetics Launches The ILUSTRA™ Inflammation Management Program | Waltham, MA — Interleukin Genetics, Inc. (OTCQB:ILIU) a life science company focused on the genetics of chronic inflammation, today unveiled the ILUSTRA™ Inflammation Management Program. The program targets individuals at elevated risk for ... |
| 31.10.2016 | Bay City Capital Partners with TDI, Takeda and Deerfield Management to Launch Bridge Medicines | New York, NY and Osaka, Japan — Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partn... |
| 20.10.2016 | Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in NASH Patients | Conshohocken, PA — Madrigal Pharmaceuticals, Inc. (MDGL) today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of non-alcoholic steatohepatitis (NASH). MGL-3196 is a first-in-class, oral, o... |
| 19.10.2016 | Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody | UTRECHT, The Netherlands — Merus N.V. (NASDAQ: MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company received an undisclosed milestone payment from Ono Pharm... |
| 11.10.2016 | Cydan Announces the Promotion of James McArthur, Ph.D. to President, Research and Development | Cambridge, MA — Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, announced the promotion of James McArthur, Ph.D. to president, research ... |
| 19.09.2016 | EnteroMedics Announces Receipt of Notice of Intention to Grant European Patent | St. Paul, MN — EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the European Patent Office has ... |
| 15.09.2016 | Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline | Cambridge, MA — Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from GlaxoSmithKline (GSK). The milestone payment f... |
| 14.09.2016 | Alexandria Summit – Healthcare Economics 2016 | David Beier
September 14-15, 2016
New York, NY
Event link |
| 06.09.2016 | Nevro Announces Two-Year SENZA-RCT Results in Neurosurgery | Redwood City, CA — Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced the publication of long-term data for the treatment of chr... |
| 24.08.2016 | First Closing Of The Earlybird Health Tech Fund | Berlin, Germany — Earlybird Venture Capital (www.earlybird.com) announces the first closing of its Earlybird Health Tech Fund. Headquartered in North Rhine-Westphalia, the fund will invest primarily in the field of medical technology across... |
| 03.08.2016 | Interleukin Genetics Strengthens Commercial Leadership with Key Appointments | Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life science company focused on the genetics of chronic inflammation, today announced the appointment of two senior leaders to enhance its commercial team and capabilities. Stephan T... |
| 01.08.2016 | Interleuken Genetics Announces $5.6M Financing | Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that it has entered into an ag... |
| 26.07.2016 | Vtesse Secures Additional $17M in Series A Extension | Gaithersburg, MD – Vtesse, Inc. a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, announced today that it has secured $17 million in additional Series A funding in support of ... |
| 22.07.2016 | Madrigal Pharmaceuticals Completes Merger with Synta | Fort Washington, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabo... |
| 12.07.2016 | Interleukin Genetics To Offer Inflammation Management Program To Amway Employees | Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation announced today that it has signed an agreement with Amway, a leading direct selling company, to provide Interle... |
